Preventing Staphylococcal (Staph) Infection
Staphylococcal Infections
About this trial
This is an interventional prevention trial for Staphylococcal Infections focused on measuring mupirocin, prevention and control, s. aureus
Eligibility Criteria
Inclusion Criteria: All patients who receive care at Ann Arbor VA Medical Center, University of Michigan Medical Center, or St. Joseph Mercy Hospital, Ypsilanti who have been hospitalized for documented S. aureus infection will be eligible for enrollment. Staphylococcal infections may be community or hospital-acquired. Patients with S. aureus infection will be identified on a daily basis with the assistance of the Infection Control Practitioner, the Clinical Microbiology Laboratory, the Infectious Diseases Consultation Services, and Infectious Diseases physicians caring for patients in their offices. Patients will provide written informed consent. The patient's guardian or next of kin will be contacted for informed consent in the event that the patient is incapable of doing so. Exclusion Criteria: Patients who are unable to cooperate with treatment or follow-up. Patients who are not likely to survive beyond one month or those who are transferred back to another acute care hospital. Patients who require treatment with rifampin will be excluded since this drug is effective in decolonization of some staphylococcal carriers. Patients with known hypersensitivity to mupirocin ointment or polyethylene glycol base. Patients with ulcers obviously related to pressure will be excluded because they are frequently large, difficult to keep clean, and infections are difficult to diagnose. Patients with small vascular or neuropathic ulcers < 3 cm in circumference and < 2 cm in depth may be enrolled. Pregnant women.
Sites / Locations
- VA Ann Arbor Healthcare System
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Mupirocin Ointment [Treatment]
Polyethylene Glycol Ointment [Placebo]
Treatment arm or active comparator [mupirocin 2% polyethylene glycol (PEG) ointment] will be compared with its placebo comparator [polyethylene glycol (PEF) in patients with a prior history of S. aureus infection. Drug or placebo will be applied topically to nares and/or wounds twice daily for 14 days at 3 month intervals for up to 18 months
Treatment arm or active comparator [mupirocin 2% polyethylene glycol (PEG) ointment] will be compared with its placebo comparator [polyethylene glycol (PEF) in patients with a prior history of S. aureus infection. Drug or placebo will be applied topically to nares and/or wounds twice daily for 14 days at 3 month intervals for up to 18 months